169 related articles for article (PubMed ID: 35238576)
1. Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
Wu S; Huang Y; Wang T; Li K; Lu J; Huang M; Dong G; Sheng C
J Med Chem; 2022 Mar; 65(6):4818-4831. PubMed ID: 35238576
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors.
Zhu F; Meng X; Liang H; Sheng C; Dong G; Liu D; Wu S
Bioorg Chem; 2022 May; 122():105702. PubMed ID: 35286923
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
Liu M; Gao S; Liang T; Qiu X; Yang X; Fang H; Hou X
J Med Chem; 2022 Sep; 65(18):12200-12218. PubMed ID: 36097406
[TBL] [Abstract][Full Text] [Related]
6. Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.
Huang Y; Chen S; Wu S; Dong G; Sheng C
Acta Pharm Sin B; 2020 Jul; 10(7):1294-1308. PubMed ID: 32874829
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L
J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
[TBL] [Abstract][Full Text] [Related]
10. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel HDAC inhibitors with a 3-(benzazol-2-yl)quinoxaline framework.
Yang Y; Liu Q; Wang X; Gou S
Bioorg Med Chem Lett; 2023 May; 88():129305. PubMed ID: 37116762
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
[TBL] [Abstract][Full Text] [Related]
14. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
16. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y
Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]